Elmer Alegre, MD
Internal Medicine · Reno, NVNPI 1013009513
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Eisai Inc. at 40.5% of the total. Reporting peaked in 2022 at $203 and has fallen 78.2% since, to $44 in 2025. That places this record below the midpoint for internal medicine clinicians in NV, where the typical reported total is $253.
Across 9 payments — averaging $34.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$125
- Organogenesis Inc.$41
- Averitas Pharma Inc.$37
- Tactile Systems Technology Inc$26
- Hologic Sales And Service, LLC$24
- Otsuka America Pharmaceutical, Inc.$21
- plus $35 from 2 others
What the payments were for
- Food & beverage$309100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 1 | $125 |
| Organogenesis Inc. | 1 | $41 |
| Averitas Pharma Inc. | 2 | $37 |
| Tactile Systems Technology Inc | 1 | $26 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Melinta Therapeutics, LLC | 1 | $16 |
How this compares
$309 in reported general payments places this provider in the 50th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $65,286 |
| EliquisApixaban | 64 | $36,936 |
| JardianceEmpagliflozin | 42 | $25,168 |
| TradjentaLinagliptin | 63 | $21,592 |
| JanuviaSitagliptin Phosphate | 22 | $13,127 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,125 |
| Famotidine | 86 | $6,510 |
| Tolterodine Tartrate ErTolterodine Tartrate | 22 | $5,018 |
| Pravastatin Sodium | 38 | $3,603 |
| Rosuvastatin Calcium | 63 | $3,429 |
| Meloxicam | 34 | $3,336 |
| Metoprolol Succinate | 139 | $3,070 |
| Ondansetron OdtOndansetron | 26 | $2,687 |
| Losartan Potassium | 134 | $2,663 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $2,585 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Reno
- Michael BlochReno$475K
- Steven ZellReno$25K
- Nirmala SurapaneniReno$11K
- Kevin DunsmoorLas Vegas$241K
- Ryan HamptonHenderson$233K
- Robert ChiascioneLas Vegas$174K
- Dino GonzalezLas Vegas$126K
- Rosanne SugayLas Vegas$63K
- Chad HallLas Vegas$42K
- Zubin DamaniaLas Vegas$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.